Key result
CKMT2 overexpression protects against hypoxia/reoxygenation injury via preserved mitochondrial function dependent on Y368 phosphorylation.
Why the study?
Ischemic preconditioning can confer cardioprotection against ischemic cardiomyopathy through mitochondrial function regulation, but the role of novel phosphorylated mitochondrial proteins remains unclear.
Does CKMT2 overexpression and phosphorylation at specific tyrosine residues confer cardioprotection against hypoxia/reoxygenation injury in cardiomyocyte models?
Does CKMT2 overexpression and phosphorylation at specific tyrosine residues confer cardioprotection against hypoxia/reoxygenation injury in cardiomyocyte models?
Regulation of quantitative expression and phosphorylation at the Y368 site of CKMT2 offers a potential novel mechanism for ischemic cardiomyopathy therapeutics.
Identifies CKMT2 Y368 phosphorylation as a potential target; hypothesis-generating in animal models and should not yet change practice.
OBJECTIVE: Ischemic cardiomyopathy (ICM) is the leading cause of heart failure. Proteomic and genomic studies have demonstrated ischemic preconditioning (IPC) can assert cardioprotection against ICM through mitochondrial function regulation. Considering IPC is conducted in a relatively brief period, regulation of protein expression also occurs very rapidly, highlighting the importance of protein function modulation by post-translational modifications. This study aimed to identify and analyze novel phosphorylated mitochondrial proteins that can be harnessed for therapeutic strategies for preventing ischemia/reperfusion (I/R) injury. METHODS: Langendorff system to simulate normal perfusion, I/R, and IPC condition, after which the samples were prepared for phosphoproteomic analysis. Employing human cardiomyocyte AC16 cells, we investigated the cardioprotective role of CKMT2 through overexpression and how site-directed mutagenesis of putative CKMT2 phosphorylation sites (Y159A, Y255A, and Y368A) can affect cardioprotection by measuring CKMT2 protein activity, mitochondrial function and protein expression changes. RESULTS: The phosphoproteomic analysis revealed dephosphorylation of mitochondrial creatine kinase (CKMT2) during ischemia and I/R, while preserving its phosphorylated state during IPC. CKMT2 overexpression conferred cardioprotection against hypoxia/reoxygenation (H/R) by increasing cell viability and mitochondrial adenosine triphosphate level, preserving mitochondrial membrane potential, and reduced reactive oxygen species (ROS) generation, while phosphomutations, especially in Y368, nullified cardioprotection by significantly reducing cell viability and increasing ROS production during H/R. CKMT2 overexpression increased mitochondrial function by mediating the proliferator-activated receptor γ coactivator-1α/estrogen-related receptor-α pathway, and these effects were mostly inhibited by Y368A mutation. CONCLUSION: These results suggest that regulation of quantitative expression and phosphorylation site Y368 of CKMT2 offers a unique mechanism in future ICM therapeutics.
No takes yet. Share an insight, caveat, or question.
Park et al. (2021) studied Ischemia/reperfusion injury. CKMT2 overexpression and site-directed mutagenesis vs. Wild type / control conditions was evaluated on Cell viability, mitochondrial ATP level, mitochondrial membrane potential, and ROS generation. CKMT2 overexpression conferred cardioprotection against hypoxia/reoxygenation by increasing cell viability and mitochondrial function, effects that were nullified by phosphomutation at Y368.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: